Evaluation of central macular thickness in diabetic patients with primary open angle glaucoma on topical latanoprost

Abstract

Purpose The aim of the study was to evaluate the changes in central macular thickness (CMT) in the eyes of diabetic patients with primary open angle glaucoma (POAG) on topical latanoprost. Design This study was designed as a prospective, interventional, comparative trial. Place The study was conducted at Ain Shams University Hospitals and at private practices. Patients and methods Twenty eyes of 12 diabetic patients with uncontrolled POAG who required topical latanoprost either as first or as additive glaucoma medication were prospectively enrolled in this study. Twenty nonglaucomatous eyes of 10 diabetic patients were included as controls. After a complete ophthalmic examination, spectral-domain optical coherence tomography and fluorescein angiography (FA) were performed at baseline before starting latanoprost. All eyes received latanoprost for 3 months, and clinical examinations were repeated 1, 2 and 3 months later; optical coherence tomography and FA were repeated after 3 months. Outcome measures were intraocular pressure (IOP), CMT and best-corrected visual acuity (BCVA). Results The mean patient age was 49 ± 11 (range 43-56) years. The mean BCVA in logMAR was 0.1 ± 0.1 (range 6/6-6/12), IOP was 24 ± 4.2 (range 19-30) mmHg, and mean CMT was 239.7 ± 26.8 (range 157-288) μm before administration of latanoprost. At 3 months' follow-up, IOP was 14.1 ± 2.9 mmHg ( P Conclusion Topical use of latanoprost for 3 months does not seem to predispose to increased CMT in diabetic patients with POAG. However, individual variations should be considered. Close observation is recommended by spectral-domain optical coherence tomography for diabetic patients on topical latanoprost.